Previous Close | 4.0300 |
Open | 4.0400 |
Bid | 3.9600 x 2200 |
Ask | 4.2000 x 1400 |
Day's Range | 3.9300 - 4.1700 |
52 Week Range | 2.2500 - 7.7800 |
Volume | |
Avg. Volume | 835,084 |
Market Cap | 261.882M |
Beta (5Y Monthly) | 0.32 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8000 |
Earnings Date | Nov 04, 2021 - Nov 08, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.40 |
Subscribe to Yahoo Finance Plus to view Fair Value for LQDA
What happened Liquidia Technologies (NASDAQ: LQDA) stock went on quite a ride during Thursday's trading session. On the back of a new analyst take on the company, its shares climbed almost 22% higher in early action before settling down to a gain of slightly over 10% on the day.
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
United Therapeutics saw its stock jump after receiving approval from the FDA to launch a new treatment for pulmonary arterial hypertension. Liquidia is pursuing a similar drug.